Epigenetic factors in breast cancer progression

Breast Cancer Metastasis and Drug Resistance: Progress and Prospects

Volumn , Issue , 2013, Pages 341-365

  Shukla, Samriddhi ^a   Meeran, Syed Musthapa ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Aromatase; Breast cancer; Breast cancer susceptibility gene 1 (BRCA1); Breast carcinogenesis; DNA methylation; Epigenetics; Histone deacetylases (HDACs); Histone modifications; Hypermethylation; Hypomethylation; Methylation sensitive transcription factors; miRNA; Selective estrogen receptor down regulators (SERDs); Selective estrogen receptor modulators (SERMs); Steroid hormone receptors

Indexed keywords

EID: 84907966435     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5647-6_19     Document Type: Chapter

References (94)

1. Greger V, Passarge E, Höpping W, Messmer E, Horsthemke B (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83(2): 155-158
2. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G (2010) Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 11: 137
3. Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21(35): 5462-5482
4. Brooks J, Cairns P, Zeleniuch-Jacquotte A (2009) Promoter methylation and the detection of breast cancer. Cancer Cause Control 20(9): 1539-1550
5. Li Y, Pan J, Li JL, Lee JH, Tunkey C, Saraf K et al (2007) Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer 6: 7
6. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC, Ibarra C et al (2007) Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13(22): 6834-6841
7. Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC et al (2009) CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18(3): 901-914
8. Lewis CM, Cler LR, Bu DW, Zöchbauer-Müller S, Milchgrub S, Naftalis EZ et al (2005) Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 11(1): 166-172
9. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM et al (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 1051-1059
10. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10(18): 6189-6193
11. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG et al. (2011) Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3(75): 75ra25
12. O'Day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12(2): 201
13. Veeck J, Esteller M (2010) Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 15(1): 5-17
14. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A et al (2011) MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 25(3): 226-231
15. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618): 455
16. Jones PA (2002) DNA methylation and cancer. Oncogene 21(35): 5358-5360
17. Lo PK, Sukumar S (2008) Epigenomics and breast cancer. Pharmacogenomics 9(12): 1879-1902
18. Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H et al (2004) DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 3(12): 1225-1231
19. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M et al (2010) Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res 30(7): 2489-2496
20. Shukla V, Coumoul X, Lahusen T, Wang RH, Xu X, Vassilopoulos A et al (2010) BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res 20(11): 1201-1215
21. Bird AP, Wolffe AP (1999) Methylation-induced repression-belts, braces, and chromatin. Cell 99(5): 451-454
22. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H et al (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23(1): 58-61
23. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP (1999) Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23(1): 62-66
24. Chatagnon A, Bougel S, Perriaud L, Lachuer J, Benhattar J, Dante R (2009) Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30(1): 28-34
25. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP (2009) Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 11(1): R14
26. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4): 286-298
27. Schübeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F et al (2004) The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18(11): 1263-1271
28. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ et al (2005) Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120(2): 169-181
29. Schneider R, Bannister AJ, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T (2004) Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol 6(1): 73-77
30. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532): 1074-1080
31. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4): 693-705
32. Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. Oncogene 23(24): 4225-4231
33. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS et al (2007) Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer 120(8): 1664-1668
34. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J et al (2008) Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6(12): 1908-1919
35. Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY et al (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25(6): 1677-1681
36. Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG (2011) EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 24(6): 786-793
37. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development, and cancer. Nat Rev Cancer 6(11): 846-856
38. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S et al (2008) Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem 283(6): 3006-3010
39. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM et al (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9): 3802-3809
40. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16): 7065-7070
41. Zhang L, Coukos G (2006) MicroRNAs: a new insight into cancer genome. Cell Cycle 5(19): 2216-2219
42. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103(24): 9136-9141
43. Calin GA (2009) MicroRNAs and cancer: what we know and what we still have to learn. Genome Med 1(8): 78
44. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283(2): 1026-1033
45. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S (2007) The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 67(22): 11001-11011
46. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163): 682-688
47. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S et al (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10(2): 202-210
48. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD et al (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175): 147-152
49. Mayr C, Hemann MT, Bartel DP (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315(5818): 1576-1579
50. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5): 635-647
51. Tsang WP, Kwok TT (2008) Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13(10): 1215-1222
52. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M (2008) MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18(5): 549-557
53. Xu X, Jin H, Liu Y, Liu L, Wu Q, Guo Y et al (2012) The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas. Diagn Pathol 7(1): 33
54. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE (2003) Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2(5): 552-556
55. Chik F, Szyf M (2011) Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32(2): 224-232
56. Girault I, Tozlu S, Lidereau R, Bièche I (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9(12): 4415-4422
57. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321(4): 591-599
58. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H et al (2003) Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylationsilenced genes in cancer cell lines. Cancer Res 63(22): 7563-7570
59. Lee WJ, Zhu BT (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27(2): 269-277
60. Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M et al (2012) Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen 17(1): 2-17
61. Singh N, Dueñas-González A, Lyko F, Medina-Franco JL (2009) Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 4(5): 792-799
62. Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM et al (2010) Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 9: 305
63. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y et al (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962-6968
64. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K et al (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94(1): 11-16
65. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN et al (2006) Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2(3): e40
66. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6(5): 873-883
67. Travaglini L, Vian L, Billi M, Grignani F, Nervi C (2009) Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41(1): 225-234
68. Li GF, Qian TL, Li GS, Yang CX, Qin M, Huang J et al (2012) Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res 11(1): 77-86
69. Li Y, Yuan YY, Meeran SM, Tollefsbol TO (2010) Synergistic epigenetic reactivation of estrogen receptor-a (ERa) by combined green tea polyphenol and histone deacetylase inhibitor in ERa-negative breast cancer cells. Mol Cancer 9: 274
70. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268(30): 22429-22435
71. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H et al (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62(17): 4916-4921
72. Konstantinopoulos PA, Vandoros GP, Papavassiliou AG (2006) FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 58(5): 711-715
73. Park H, Im JY, Kim J, Choi WS, Kim HS (2008) Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med 21(3): 325-333
74. Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9(12): 3254-3266
75. Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L et al (2000) Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res 6(3): 994-997
76. Baud MG, Leiser T, Meyer-Almes FJ, Fuchter MJ (2011) New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation. Org Biomol Chem 9(3): 659-662
77. Saxena NK, Sharma D (2010) Epigenetic reactivation of estrogen receptor: promising tools for restoring response to endocrine therapy. Mol Cell Pharmacol 2(5): 191-202
78. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1): 17-35
79. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7): 2989-2994
80. Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K (2008) Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 27(29): 4075-4085
81. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB et al (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8(1): 21-30
82. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J (1997) A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 45(3): 251-262
83. Hasmann M, Rattel B, Löser R (1994) Preclinical data for Droloxifene. Cancer Lett 84(2): 101-116
84. Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56(10): 2321-2330
85. Wijayaratne AL, McDonnell DP (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276(38): 35684-35692
86. Smith IE (2004) Aromatase inhibitors in early breast cancer therapy. Semin Oncol 31(6): 9-14
87. Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9(2): 126-136
88. Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L et al (2011) Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther 11(8): 1253-1263
89. Bosviel R, Garcia S, Lavediaux G, Michard E, Dravers M, Kwiatkowski F et al (2012) BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol 36(3): e177-e182
90. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17
91. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG et al (2009) BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 115(2): 397-404
92. Fuks F, Milner J, Kouzarides T (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17(19): 2531-2534
93. Ben Gacem R, Hachana M, Ziadi S, Amara K, Ksia F, Mokni M et al (2012) Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. Cancer Epidemiol 36(2): 190-197
94. Leung M, Rosen D, Fields S, Cesano A, Budman DR (2011) Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 17(7-8): 854-862